

### **Plexense Korea**

#### **Head Office**

B-604, 670 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, Republic ofKorea

### R&D Center

1-1301,1302, 1303, 16-4 Dongbaekjoongang-ro,16 beongil, Giheung-gu, Yongin-si, Gyeonggi-do, 17 015,Republic of Korea

### Plexense U.S.A.

#### Plexense BIO, Inc.

4136E Commerce Way, Suite 300, Sacramento, CA, 95834, U.S.A.

**VEO Diagnostics (Distribution Center)** 422 Wards Corner Rd. Suite A, Loveland,


OH, 45140,U.S.A.

### **Contact Information**

Homepage: <a href="mailto:www.plexense.com">www.plexense.com</a>
E-mail: <a href="mailto:info@plexense.com">info@plexense.com</a>


Republic of Korea: (+82) 70.4725.4681 U.S.A.: (+1)916.280.0362





# What is ACCELELISA®?

### **ACCEL ELISA®** is the **NEXT-GENERATION** immunoassayplatform



### What is ACCEL ELISA®?

ACCEL ELISA®combines a unique and proprietary well plate design with advanced surface chemistry and reagent formulation to create an innovative immunoassay platform designed to maximize speed and s ensitivity.

ACCEL ELISA®provides an increased sensitivity, simplicity, speed w hen compared to traditional ELISA techniques. Reproducible results can be achieved in 30minutes or less.

### Competitiveness

Speed	Assay results in 30 minutes
Simplicity	2-step reaction with 1-wash
Sensitivity	5-40 times higher sensitivity
Compatibility	Compatible with most antibody/antigen pairs
Cost saving	Seamless integration to existing plate readers
Reproducibility	More excellent

### **Simple Process & Fast**





30min

**Total incubation time** 

	Reaction time	Washing	Incubation
ACCEL ELISA®	30min	1(time)	2 (times)

### **Conventional ELISA**



	Reaction time	Washing	Incubation	
Conventional ELISA	4.5hr	3~5 (times)	4~7 (times)	

## **Core Technology of ACCELELISA®**

### Proprietary well design

- Application of unique well design to maximize surface.
- Increased surface area offersimproved sensitivity and maximized enzymatic r eaction.
- Build up technical barrier against co mpetitors' similar technologies with multiple well designpatents.

Wash / Ad

2hr

d conjugate/

Incubate


# Surface treatment technology

- Plexense's proprietary surface chemistry eliminates blockingstep.
- Minimized non-specific reaction that affects the results by applying unique surface trea tment to the well surface.

# Optimized reagent formulation

- Plexense's reagents are formulated to simplify immunoassay with single wash.
- Shorten protocol through technology that enables homogeneous mixing to simplify the immunoassay.

## **Diagnostic Platform**



Wash / A

dd substrate

10~30

min

4.5hr
Total incubation time

# Why choose ACCEL ELISA® over other platform for COVID-19?

### **Technical Advantage**

- Plexense has developed the world's first p roprietary plate design with advanced sur face chemistry and reagent formulation.
- ACCEL ELISA® provides excellent sensitivity compared to conventional ELISAmethods.
- Plexense's technology patented world-wide with 36 patents in US, Japan and Korea.



Innovative WellDesign



Best-in Class Bio-Markers ( 100% KoreaManufactured)

# 30min

### **Assay Time**

### Speed

Reproducible results can be achieved in 30 minutes. ACCEL ELISA® provides an increased sensitivity, simplicity, speedwhen compared to traditional ELISA techniques.

2,880 test 98.5%

### Unrestricted

The ultimate solution to address the mass testing requirements.

The ACCEL ELISA®testing can be deployed under minimized laboratory conditions with the least amount of resources and without highly trained technicians. This is the ultimate solution to address the rapidly surging case of COVID-19 worldwide.

**Overall Agreement with RT-PCR** 


#### Accuracy

The ACCEL ELISA®detects IgG, IgM, IgA, antibodies to COVID-19 virus and provides a high level of accuracy similar to RT-PCR testing method.

# **Simple Process**

### RT-PCR

### **ACCEL ELISA®**



#### **ACCEL ELISA® COVID-19**

		Positive	Negative	Total	%
PCR	Positive	85	5	90	94.4%
	Negative	0	251	251	100%
	Total	85	256	341	98.5%

### 5th day 100% upon infection


Days upon infection	Positive %	Negative%
1~4	66.7%	100%
5~10	100%	100%
≥ 11	100%	100%

Approved by KoreaResearch Institute of Bioscience and B iotechnology

- Clinical sample provider: Korea Institute of Radiological & Medical Sciences
- Evaluation institution: Bio Nano Health Guard Research Center
- Evaluation period : May 14~16,2020

# Easy scale-up to any testing capacity


The ACCEL ELISA® allows for quick and easy scale-up to any testing capacity in very short period of time (e.g. 1,000 test per day capacity to 10,000 tests per day capacity can be s caled-up in less than 1week) - making it the most ideal platform for mass testing at ultra- h igh throughput areas such as airports, borders, sports stadiums, schools, etc.



# **ACCEL ELISA®COVID-19**

### How does it work?

### **Sample Preparation Sequence**



STEP 6

Pouring a TM

**B** Substrate

Incubation Time

STEP 4

Mixing

20min

STEP 5

**Incubating & Washing** 

10min

STEP7

**Incubating & Analysis** 

Product Package

The ACCEL ELISA® COVID 19 assay uses SA R S CoV 2 nucleocapsid protein(N protein) custo m developed by the BioNano Health Guard Res earch Center (a division of the Ministry of S cie nce and ICT, Korea) in collaboration with Kore a Research Institute of Bioscience and Biotechn ology (KRIBB) for the prior use of COVID 19 anti body detection on ACCEL ELISA® platform.




For the Detection of Total Antibody to SARS-CoV-2 in Serum










### **COVID-19** antigen coated microplate

COVID-19 antigen

96 well microplate (packaged in aluminium foil)

Packaged in aluminium foil



Platform	Product Name	Detection	Product Code
	Plexense ACCEL ELISA®COVID-19Kit	IgG/IgM/IgA (Total antibody)	AE301
ACCEL	Plexense ACCEL ELISA® COVID-19 Saliva Antigen Kit	COVID-19 Antigen	AE302
ELISA®	Plexense ACCEL ELISA® COVID-19 Neutralizing Antibody Kit	COVID-19 Neutralizing antibody	AE303





TMB Substrate

ACCEL ELISA

COVID-19 Kit

REF AE301







Positive

30 uL ACCEL ELIS

Negativ

ACCEL EL



Quantity:1vial Liquid reagent



10X Wash Buffer
Quantity:1vial
Liquid reagent



Ī	Sample
CJ (B) C-	Dilution Buffer
d	Quantity:1vial
	Liquid reagent